The stock gained 4.3 per cent to close at an all-time high of Rs 345.30, on reports that the company is in talks with Pfizer, world’s largest drug maker, to supply generic products for their drugs. As an ongoing business strategy, the company is seeking alliance with other companies for developing products.
The company, which does not market its formulations directly in major markets like the US, follows a business partnership model of supplying products to about 14 drug companies around the world.